506197 Stock Overview
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India.
Bliss GVS Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹71.45|
|52 Week High||₹128.40|
|52 Week Low||₹66.25|
|1 Month Change||-11.79%|
|3 Month Change||-16.92%|
|1 Year Change||-34.18%|
|3 Year Change||-56.59%|
|5 Year Change||-62.25%|
|Change since IPO||27,978.63%|
Recent News & Updates
|506197||IN Pharmaceuticals||IN Market|
Return vs Industry: 506197 underperformed the Indian Pharmaceuticals industry which returned -10.9% over the past year.
Return vs Market: 506197 underperformed the Indian Market which returned 10.5% over the past year.
|506197 Average Weekly Movement||7.0%|
|Pharmaceuticals Industry Average Movement||7.0%|
|Market Average Movement||7.3%|
|10% most volatile stocks in IN Market||10.0%|
|10% least volatile stocks in IN Market||4.8%|
Stable Share Price: 506197 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 506197's weekly volatility (7%) has been stable over the past year.
About the Company
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes.
Bliss GVS Pharma Fundamentals Summary
|506197 fundamental statistics|
Is 506197 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|506197 income statement (TTM)|
|Cost of Revenue||₹3.91b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||1.45|
|Net Profit Margin||2.01%|
How did 506197 perform over the long term?See historical performance and comparison
0.7%Current Dividend Yield
Does 506197 pay a reliable dividends?See 506197 dividend history and benchmarks
|Bliss GVS Pharma dividend dates|
|Ex Dividend Date||Jun 20 2022|
|Dividend Pay Date||Jul 28 2022|
|Days until Ex dividend||31 days|
|Days until Dividend pay date||69 days|
Does 506197 pay a reliable dividends?See 506197 dividend history and benchmarks
Is Bliss GVS Pharma undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 506197 (₹71.45) is trading below our estimate of fair value (₹847.86)
Significantly Below Fair Value: 506197 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 506197 is poor value based on its PE Ratio (49.3x) compared to the Indian Pharmaceuticals industry average (21.7x).
PE vs Market: 506197 is poor value based on its PE Ratio (49.3x) compared to the Indian market (20.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 506197's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 506197 is good value based on its PB Ratio (0.9x) compared to the IN Pharmaceuticals industry average (2.6x).
How is Bliss GVS Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bliss GVS Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Bliss GVS Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 506197 has a large one-off loss of ₹735.9M impacting its March 31 2022 financial results.
Growing Profit Margin: 506197's current net profit margins (2%) are lower than last year (11.9%).
Past Earnings Growth Analysis
Earnings Trend: 506197's earnings have declined by 8.2% per year over the past 5 years.
Accelerating Growth: 506197's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 506197 had negative earnings growth (-78%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.5%).
Return on Equity
High ROE: 506197's Return on Equity (2.7%) is considered low.
How is Bliss GVS Pharma's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 506197's short term assets (₹7.8B) exceed its short term liabilities (₹2.3B).
Long Term Liabilities: 506197's short term assets (₹7.8B) exceed its long term liabilities (₹292.0M).
Debt to Equity History and Analysis
Debt Level: 506197 has more cash than its total debt.
Reducing Debt: 506197's debt to equity ratio has reduced from 40.7% to 12.4% over the past 5 years.
Debt Coverage: 506197's debt is well covered by operating cash flow (129.1%).
Interest Coverage: 506197's interest payments on its debt are well covered by EBIT (21.3x coverage).
What is Bliss GVS Pharma current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 506197's dividend (0.7%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).
High Dividend: 506197's dividend (0.7%) is low compared to the top 25% of dividend payers in the Indian market (1.57%).
Stability and Growth of Payments
Stable Dividend: 506197's dividend payments have been volatile in the past 10 years.
Growing Dividend: 506197's dividend payments have fallen over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (34.2%), 506197's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (8.4%), 506197's dividend payments are thoroughly covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gagan Sharma (38 yo)
Mr. Gagan Harsh Sharma serves as Managing Director & Director at Bliss GVS Pharma Limited since May 11, 2021. He served as Vice President of Strategy and Business Development at Bliss Gvs Pharma Limited un...
CEO Compensation Analysis
Compensation vs Market: Gagan's total compensation ($USD16.85K) is below average for companies of similar size in the Indian market ($USD38.73K).
Compensation vs Earnings: Insufficient data to compare Gagan's compensation with company performance.
Experienced Management: 506197's management team is considered experienced (3.8 years average tenure).
Experienced Board: 506197's board of directors are considered experienced (8.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 506197 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bliss GVS Pharma Limited's employee growth, exchange listings and data sources
- Name: Bliss GVS Pharma Limited
- Ticker: 506197
- Exchange: BSE
- Founded: 1984
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹7.408b
- Shares outstanding: 103.68m
- Website: https://www.blissgvs.com
Number of Employees
- Bliss GVS Pharma Limited
- 102, Hyde Park
- Saki Vihar Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.